Taken together the anti-inflammatory and anti-steatotic effects of a sEH inhibitor and the positive effects after FXR activation in NASH with an FXR agonist, it shows clearly the potential of a dual sEH/FXR modulator in this disease. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.